Shots:
- The two OLE P-III 1489 and 1490 studies assessing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) vs dolutegravir-containing triple for the treatment of HIV-1 in treatment naïve adults
- The study demonstrated the sustained efficacy & safety profile with no treatment-emergent resistance @144wks, >98% of treatment-naïve patients achieved and maintained undetectable viral load @4yrs.; viral suppression in 48wks. OLE period
- In a subgroup analysis of patients with TDR, Biktarvy achieved comparably high levels of durable viral suppression @144 weeks among participants with and without TDR (98% vs 97%; as treated analysis)
Click here to read full press release/ article | Ref: Businesswire | Image: Devex
The post Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021 first appeared on PharmaShots.
